CTOs on the Move

BioSkryb

www.bioskryb.com

 
Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioSkryb raised $11.5M on 01/08/2020

Similar Companies

AiLife Diagnostics

AiLife Diagnostics is a CAP/CLIA laboratory that provides end-to-end genomic testing, interpretation services, and NGS analysis tool.

Western Oncolytics

Western Oncolytics is developing a new generation of oncolytic viral immunotherapies to help patients accross the globe beat cancer

Point Biopharma

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

Artiva Biotherapeutics

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva`s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

RNAimmune

RNAimmune is a biotechnology startup in the field of messenger RNA (mRNA) technology with more than 20 years expertise in handling and optimizing this versatile molecule for medical purposes. The principle of RNAimmune`s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.